drugset / Trial / NCT02956278
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
Phase 4
Completed
27 enrolled
University of California, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabOpen Medicine Institute · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.
Timeline
- Start
- 2016-11
- Primary completion
- 2018-03
- Completion
- 2018-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allopurinol | Small molecule | 300 mg | — |